Answers are grounded in this paper and cite their sources.
Evaluates vinorelbine's impact on oncolytic virus effectiveness in ovarian cancer, suggesting improved treatment options.
cell death via apoptosis. In a syngeneic mouse model of high-grade serous ovarian carcinoma, ΔVF virus lacking the viral thymidine kinase (TK), armed with granulocyte-macrophage colony-stimulating factor (GM-CSF), and expressing NeonGreen (ΔVFTK-NG-GM-CSF) is tumor-specific. A combination of the ΔVFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests that vinorelbine is a promising agent to combine with oncolytic vaccinia virus for the management of ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Drymiotou et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: